Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lou Gehrig's Disease Clear all
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen C CNM-Au8

NCT04414345
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CNM-Au8, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 4, 2026, 4:36 PM EDT
Terminated Phase 2 Interventional

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

NCT04428775
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALZT-OP1a (cromolyn)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
La Jolla, California • Jacksonville, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Not applicable Interventional Results available

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

NCT00116558
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Early NIPPV, Standard NIPPV
Device
Lead sponsor
Edward Kasaraskis
Other
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
12
States / cities
Denver, Colorado • Miami, Florida • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00125203
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Sialorrhea
Interventions
Botulinum toxin type B (Myobloc), Injection of salivary glands
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Kansas City, Kansas • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen A Zilucoplan

NCT04436497
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 4, 2026, 4:36 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Masitinib (6.0), Riluzole, Placebo, Masitinib (4.5)
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 81 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2Phase 3 Interventional

Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement

NCT00386464
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
noninvasive positive pressure ventilation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2007 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen D Pridopidine

NCT04615923
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of High Dose CoQ10 in ALS

NCT00243932
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Interventions
coenzyme Q10, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
19
States / cities
Little Rock, Arkansas • San Francisco, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 4, 2026, 4:36 PM EDT
Withdrawn Phase 2 Interventional

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

NCT00561366
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, Arimoclomol
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Pacific Palisades, California • San Francisco, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 4, 2026, 4:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Familial and Sporadic ALS

NCT00821132
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis, ALS With Frontotemporal Dementia (ALS/FTD), Lou Gehrig's Disease, Motor Neuron Disease (MND), Primary Lateral Sclerosis (PLS), Sporadic ALS (SALS)
Interventions
Genetic study of ALS families
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
13,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 4, 2026, 4:36 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00420719
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Intramuscular diaphragm electrodes
Device
Lead sponsor
Synapse Biomedical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
7
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT01257581
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine, tamoxifen
Drug
Lead sponsor
Nazem Atassi
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

NCT02039401
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VM202
Biological
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
21 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 4, 2026, 4:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

NCT00677768
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Primary Lateral Sclerosis, Nervous System Diseases, Hereditary Spastic Paraparesis
Interventions
No intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 80 Years
Enrollment
475 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
29
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen B Verdiperstat

NCT04436510
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Matching Placebo, Verdiperstat
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

NCT02450552
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ezogabine, Placebo
Drug
Lead sponsor
Brian Wainger
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

Mexiletine for the Treatment of Muscle Cramps in ALS

NCT01811355
View directory record Official record
Conditions
Muscle Cramps in Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
Bjorn Oskarsson, MD
Other
Eligibility
21 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Chester, California • La Jolla, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 4, 2026, 4:36 PM EDT
Recruiting Phase 2 Interventional

A Study of Ranolazine in ALS

NCT06527222
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Swathy Chandrashekhar, MBBS
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Fairway, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 4, 2026, 4:36 PM EDT
Active, not recruiting Phase 2 Interventional

T-regulatory Cells in ALS

NCT04055623
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00748501
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SB-509
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
La Jolla, California • Orange, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 4, 2026, 4:36 PM EDT
Completed No phase listed Observational Results available

A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients

NCT00786032
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
BCI Device
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 79 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
West Haven, Connecticut • Albany, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 1Phase 2 Interventional

Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis

NCT00956488
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Lou Gehrig's Disease
Interventions
Treadmill Exercise
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 4, 2026, 4:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

NCT05136885
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SLS-005, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 4, 2026, 4:36 PM EDT